Do you have Eosinophilic Granulomatosis with Polyangiitis (EGPA – Churg Strauss Syndrome)?

Are you taking a daily, high dose of corticosteroids, such as prednisone or prednisolone?

And are you interested in taking part in a clinical trial to test a new treatment?

AstraZeneca is looking for people with EGPA to take part in a clinical trial called MANDARA1. MANDARA will be investigating whether an investigational product is safe and can provide benefit to people with EGPA.

Who can join?

MANDARA may be suitable for you if you:

- Are aged 18 years or older
- Have been diagnosed with EGPA for at least 6 months
- Have been experiencing EGPA symptoms, despite being treated with high doses of corticosteroids such as prednisolone of more than 7.5 mg per day

Why participate?

The findings of this study will be used to help develop new EGPA treatments.

If you are eligible to take part, you:

- Will receive expert medical care, related to the study, at no cost to you
- May receive compensation, relating to time and travel costs
- Will help make a difference for people diagnosed with EGPA in the future

If you are interested in taking part in the MANDARA study, please speak with your doctor today.

Email: information.center@astrazeneca.com
Phone: 1-877-240-9479
www.mandarastudy.com

1 MANDARA is a lake in the middle of a desert. This is very rare, much like a disease such as EGPA.